Form 4: Teladoc Health Executive Sells Shares Under 10b5-1 Plan

Teladoc Health's President of U.S. Group Health, Kelly Bliss, has sold 2,500 shares of common stock as part of a pre-arranged trading plan.

Summary

• Kelly Bliss, President of U.S. Group Health at Teladoc Health, Inc., sold 2,500 shares of common stock on June 29, 2026.
• The transaction was executed at a price of $8.50 per share.
• Following this transaction, Bliss beneficially owns 89,878 shares of common stock.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on August 14, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• The filing is a Form 4, indicating a change in beneficial ownership of securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be a negative signal, the execution under a pre-established 10b5-1 plan indicates a planned divestment rather than a reaction to adverse company news.

Negatives

• An executive has sold a portion of their holdings, which could be perceived negatively by the market, although it was executed under a pre-planned trading strategy.

Risks

• The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by the market as a lack of confidence in the company's near-term prospects.
• While the 10b5-1 plan is a standard compliance tool, the actual sale of shares reduces the executive's direct stake in the company.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event in the telehealth and digital health industry. Such transactions are closely watched by investors for potential signals about management's confidence, though the existence of a pre-arranged plan mitigates concerns about opportunistic trading.

Stakeholder Impact

• Shareholders: May interpret the sale as a minor negative signal, though mitigated by the 10b5-1 plan. The executive's continued substantial ownership limits significant negative impact.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers/Customers: No direct impact mentioned.

Next Steps

• Continued monitoring of insider transactions for any further changes in beneficial ownership.
• Observation of Teladoc Health's stock performance and company announcements for broader strategic insights.

Key Dates

Keywords

Teladoc Health, TDOC, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Beneficial Ownership, Kelly Bliss